1. COVID‐19, liver transplant, and immunosuppression: Allies or foes?
- Author
-
Paolo Muiesan, Tommaso Maria Manzia, Fabio Tirotta, Marialuisa Framarino dei Malatesta, Alessandro Parente, Giuseppe Tisone, and Roberta Angelico
- Subjects
Adult ,Graft Rejection ,Male ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Adolescent ,medicine.drug_class ,medicine.medical_treatment ,Short Communication ,030230 surgery ,Liver transplantation ,Antimetabolite ,03 medical and health sciences ,Immunocompromised Host ,Young Adult ,0302 clinical medicine ,COVID‐19 ,medicine ,Immunological status ,Humans ,Intensive care medicine ,Child ,Transplantation ,liver transplantation ,business.industry ,SARS-CoV-2 ,Normal population ,COVID-19 ,Immunosuppression ,Middle Aged ,Transplant Recipients ,Settore MED/18 ,liver transplant ,Infectious Diseases ,New disease ,030211 gastroenterology & hepatology ,Female ,business ,Immunosuppressive Agents - Abstract
Liver transplant (LT) recipients are considered at a particularly high risk for developing critical COVID‐19 infection. To date, available data are heterogeneous and scarce and mortality in LT recipients seems to be higher compared to normal population, but whether this is caused by altered immunological status, immunosuppression (IS), or underlying comorbidities has not yet been fully clarified. Some evidences show that IS might play a role in the pathophysiology of this new disease. We searched all available data regarding LT recipients infected by COVID‐19, focusing on the role of IS. To date, 244 LT recipients have been reported as COVID‐19‐positive. Trends among transplant physicians are to reduce overall IS, especially antimetabolite drugs, but the current available observations are still not enough to build strong evidences for recommendation and IS should be meticulously tailored case by case.
- Published
- 2020
- Full Text
- View/download PDF